UroGen Pharma
(NASDAQ) URGN
UroGen Pharma Financials at a Glance
Market Cap
$1.68B
Revenue (TTM)
$140.49M
Net Income (TTM)
-$133.23M
EPS (TTM)
-$2.76
P/E Ratio
-12.48
Dividend
$0.00
Beta (Volatility)
1.00 (Low)
Dividend
$0.00
Beta (Volatility)
1.00 (Low)
Price
$34.50
Volume
1,348,411.093
Open
$34.29
Price
$34.50
Volume
1,348,411.093
Open
$34.29
Previous Close
$34.54
Daily Range
$33.73 - $35.10
52-Week Range
$12.73 - $36.08
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.00 (Low)
Price
$34.50
Volume
1,348,411.093
Open
$34.29
Previous Close
$34.54
Daily Range
$33.73 - $35.10
52-Week Range
$12.73 - $36.08
Estimated Earnings Date
Aug 6, 2026
URGN News
URGN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout UroGen Pharma
Industry
Biotechnology
Sector
Health CareEmployees
291
CEO
Elizabeth Barrett, MBA
Website
www.urogen.comHeadquarters
Princeton, NJ 08540, US
URGN Financials
Key Financial Metrics (TTM)
Gross Margin
89.85%
Operating Margin
-77.02%
Net Income Margin
-94.83%
Return on Equity
121.52%
Return on Capital
-546.26%
Return on Assets
-52.51%
Earnings Yield
-8.01%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.68B
Shares Outstanding
48.72M
Volume
1.35M
Avg. Volume
782.49K
Financials (TTM)
Gross Profit
$126.24M
Operating Income
-$108.21M
EBITDA
-$115.78M
Operating Cash Flow
-$165.74M
Capital Expenditure
-$299.00K
Free Cash Flow
-$166.04M
Cash & ST Invst.
$141.60M
Total Debt
$197.09M
UroGen Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$50.96M
+151.6%
Gross Profit
$46.82M
+161.2%
Gross Margin
91.88%
N/A
Market Cap
$1.68B
N/A
Market Cap/Employee
$5.76M
N/A
Employees
291
N/A
Net Income
-$23.57M
+46.2%
EBITDA
-$19.00M
+51.1%
Quarterly Fundamentals
Total Cash
$141.60M
-27.7%
Total Debt
$197.09M
+57.7%
Accounts Receivable
$55.41M
+182.2%
Inventory
$20.92M
+175.6%
Long Term Debt
$195.18M
+56.2%
Short Term Debt
$1.92M
N/A
Return on Assets
-52.51%
N/A
Return on Invested Capital
-53.29%
N/A
Free Cash Flow
-$45.37M
-7.8%
Operating Cash Flow
-$45.32M
-7.8%